Skip to main content

Table 2 Mean and median levels of ovarian reserve markers (AMH, AFC and FSH) measured at baseline, during CT, 1 month and at a mean of 18 months after the end of CT

From: Adverse reproductive health outcomes in a cohort of young women with breast cancer exposed to systemic treatments

 

Baseline

During CT

1 month after CT

Last available follow-up

 AMH ng/mL

Mean ± SD (median)

3.07 ± 2.95 (2.20)

n = 38

0.30 ± 0.50 (0.06)

n = 21

0.15 ± 0.461 (0.06)

n = 30

0.32 ± 0.681,3 (0.06)

n = 34

 AFC

Mean ± SD (median)

10.6 ± 5.2 (9.0)

n = 35

4.1 ± 3.5 (4.0)

n = 19

3.4 ± 6.82 (1.0)

n = 25

2.2 ± 3.01 (2.0)

n = 21

 FSH mIU/mL

Mean ± SD (median)

7.1 ± 5.6 (5.2)

n = 36

21.2 ± 24.2 (9.1)

n = 21

64.3 ± 47.81 (64)

n = 28

21.4 ± 36.94 (6.4)

n = 35

  1. AFC antral follicle count, AMH anti-Mullerian hormone, CT chemotherapy, FSH follicle-stimulating hormone
  2. SD standard deviation
  3. 1 as compared to baseline, p<0.001; 2 as compared to baseline, p = 0.001; 3 as compared to the previous follow-up, p = 0.03;
  4. 4as compared to the previous follow-up, p<0.001